clopidogrel tad
tad pharma gmbh - clopidogrel (as hydrochloride) - peripheral vascular diseases; stroke; myocardial infarction - antitromboziniai vaistai - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
emlodin
egis pharmaceuticals plc - amlodipinas - tabletės - 10 mg; 2,5 mg; 5 mg - amlodipine
zomig
astrazeneca uk limited - zolmitriptanas - plėvele dengtos tabletės - 2,5 mg - zolmitriptan
telmisartan egis
egis pharmaceuticals plc - telmisartanas - plėvele dengtos tabletės - 80 mg; 40 mg; 20 mg - telmisartan
orladeyo
biocryst ireland limited - berotralstat dihydrochloride - angioedema, paveldima - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.
protopic
leo pharma a/s - takrolimuzas - dermatitas, atopinis - kiti dermatologiniai preparatai - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids. maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i. pasitaikančių keturis ar daugiau kartų per metus), kurie turėjo pradinis atsakas į šešių savaičių gydymo du kartus per parą, takrolimuzas tepalas (pažeidimų pašalinta, beveik išvalytas arba mažai įtakos).
quviviq
idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - miego inicijavimo ir priežiūros sutrikimai - psicholeptikai - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.
thalidomide bms (previously thalidomide celgene)
bristol-myers squibb pharma eeig - talidomidas - daugybinė mieloma - imunosupresantai - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.
atorvastatin tad
tad pharma gmbh - atorvastatinas - plėvele dengtos tabletės - 20 mg; 10 mg; 40 mg - atorvastatin
drewnochron impregnat grunt giliai įsiskverbiantis (bespalvis)
ppg deco polska sp. z o.o., ul. kwidzynska 8, 51-416 wroclaw (lenkija) - 1-(4-chlorfenil)-4,4-dimetil-3-(1,2,4-triazol-1-ilmetill)pentan-3-olis, tebukonazolis, preventol a8; 1-(4-chlorfenil)-4,4-dimetil-3-(1,2,4-triazol-1-ilmetill)pentan-3-olis, tebukonazolis, preventol a8; 1-(4-chlorfenil)-4,4-dimetil-3-(1,2,4-triazol-1-ilmetill)pentan-3-olis, tebukonazolis, preventol a8 - veikliosios medžiagos cas nr.: 107534-96-3, eb nr.: 403-640-2, veikliosios medžiagos pavadinimas: 1-(4-chlorfenil)-4,4-dimetil-3-(1,2,4-triazol-1-ilmetill)pentan-3-olis, tebukonazolis, preventol a8, koncentracija: 0.3% , veiklioji; veikliosios medžiagos cas nr.: 107534-96-3, eb nr.: 403-640-2, veikliosios medžiagos pavadinimas: 1-(4-chlorfenil)-4,4-dimetil-3-(1,2,4-triazol-1-ilmetill)pentan-3-olis, tebukonazolis, preventol a8, koncentracija: 0.3% , veiklioji; veikliosios medžiagos cas nr.: 107534-96-3, eb nr.: 403-640-2, veikliosios medžiagos pavadinimas: 1-(4-chlorfenil)-4,4-dimetil-3-(1,2,4-triazol-1-ilmetill)pentan-3-olis, tebukonazolis, preventol a8, koncentracija: 0.3% , veiklioji - medienos konservantai